Advertisement

Topics

Latest "OPKO Health Reference Laboratories" News Stories

20:15 EDT 23rd September 2018 | BioPortfolio

Here are the most relevant search results for "OPKO Health Reference Laboratories" found in our extensive news archives from over 250 global news sources.

More Information about OPKO Health Reference Laboratories on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about OPKO Health Reference Laboratories for you to read. Along with our medical data and news we also list OPKO Health Reference Laboratories Clinical Trials, which are updated daily. BioPortfolio also has a large database of OPKO Health Reference Laboratories Companies for you to search.

Showing "OPKO Health Reference Laboratories" News Articles 1–25 of 25,000+

Extremely Relevant

Opko Health (OPK) and Haemonetics (HAE) Financial Survey

Opko Health and Haemonetics are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk. Opko Health currently has a consensus price target of $12.10, suggesting a potential upside of 270.03%.


SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OPKO Health - OPK

NEW YORK, Sept. 14, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of OPKO Health ("OPKO" or the "Company") (NASDAQ: OPK). Such investors are advised to contact ...

Pomerantz LLP: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OPKO Health, Inc. - OPK

NEW YORK, NY / ACCESSWIRE / May 22, 2018 / Pomerantz LLP is investigating claims on behalf of investors of OPKO Health, Inc. ("OPKO" or the "Company") (NASDAQ: OPK). Such investors are advised to ...


OPKO Health completes enrolment in Phase lll trial of somatrogon

OPKO Health has completed enrolment in a global pivotal Phase lll trial of somatrogon (hGH-CTP) for the treatment of growth...Read More... The post OPKO Health completes enrolment in Phase lll trial of somatrogon appeared first on Drug Development Technology.

Relevant

OPKO Health Reports First Quarter 2018 Financial Results

OPKO Health (NASDAQ:OPK) reports financial results and business highlights for the three months ended March 31, 2018. As quoted in the press release: “We are pleased to report steady sequential-quarter growth for RAYALDEE and 4Kscore, as well as improvement in our lab business from Q4 of last year,” said Phillip Frost, Chairman and Chief Executive Officer of … Continued The post OPKO H...

Active-Investors: Wired News - OPKO Health Announced Enrollment of First Patient in Phase-2b Trial of OPK88003 to Treat Type-2 Diabetes

Stock Monitor: Capricor Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free research report on OPKO Health, Inc. (NASDAQ: ...

Merck enters agreement with HistoCyte Laboratories for distribution of reference products

Science and technology company, Merck, has entered into an agreement with HistoCyte Laboratories, for the distribution of its portfolio of cell line reference products for immunohistochemistry and in situ hybridisation.

Hagens Berman Alerts Investors in OPKO Health (OPK) to the Firm's Investigation of Possible ...

SAN FRANCISCO, Sept. 11, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in OPKO Health, Inc. (NASDAQ: OPK) to the firm's investigation into Read more...

Biotech billionaire Phillip Frost charged by SEC, sending Opko shares sliding

The SEC announced the charges Friday, alleging the Opko CEO and nine others manipulated stock prices in "classic pump-and-dump schemes."

Opko Health completes enrollment in phase 3 study of somatrogon in GHD children

The company has used multi-dose disposable pen to deliver an investigational long-acting human growth hormone product, somatrogon. Somatrogon is a new molecular entity, which maintains the natural sequence The post Opko Health completes enrollment in phase 3 study of somatrogon in GHD children appeared first on Compelo Medical Devices.

OPKO Confirms Resumption of Common Stock Trading on Nasdaq

OPKO Health, Inc. (NASDAQ: OPK) is pleased to confirm that The Nasdaq Stock Market has lifted the trading suspension of OPKO’s shares. As noted previously, OPKO and 19 other defendants, including Dr. Phillip Frost, its CEO and Chairman, were named in a Complaint filed on September 7 by the Securities and Exchange Commission (“SEC”). The Comp...

OPKO Comments on Continued Nasdaq Halt of Trading of Common Stock

OPKO Health, Inc. (NASDAQ:OPK) has had trading in its common stock halted by The Nasdaq Stock Market, and the exchange has advised OPKO that the halt will continue until the company responds (to Nasdaq’s satisfaction) to the exchange’s request for information related to the previously reported lawsuit filed by the U.S. Securities and Exchange Commissio...

OPKO Comments on SEC Complaint

OPKO Health, Inc. (NASDAQ: OPK) provided the following comment on the lawsuit filed by the U.S. Securities and Exchange Commission earlier today. “OPKO learned today that the Securities and Exchange Commission has filed a lawsuit in the Southern District of New York against a number of individuals and entities, including OPKO and its CEO and Cha...

Opko Health: The Importance Of The 4kscore Test Study

Opko Health: If These SEC Charges Were Surprising Then You Haven't Been Paying Attention

OPKO Health, Inc. (OPK) CEO Phillip Frost on Q2 2018 Results - Earnings Call Transcript

BioSci Rounds Report: Elucidating Crispr Fundamentals Improvement And Opko Health Prospects

Finance Watch: Opko's Stock Halted As Nasdaq Awaits An Explanation For SEC Pump-And-Dump Lawsuit

Public Company Edition: An SEC complaint alleges that the company, Opko CEO Frost and co-defendants bought penny stocks, pumped up...    

Get to Know Your Reference Genome (GRCh37 vs GRCh38)

Whether your experiment relies upon a reference-based genome assembly or mapping reads to a reference genome to identify variants, you need to choose a human reference genome assembly. But wait! You go to the FTP site of NCBI’s refseq and click on the Homo sapiens folder. There you are presented with two choices. Which one… The post Get to Know Your Reference Genome (GRCh37 vs GRCh38) appe...

Opko Health to delist from TASE

The company, one of the largest on the Tel Aviv Stock Exchange, joins the exodus of dual-listed US biotech companies.

OPKO Health Is A High-Risk And High-Return Stock For 2018

Merck Signs Exclusive Agreement with HistoCyte Laboratories to Distribute Pathology Technology

Merck, a leading science and technology company, has announced that it has entered into an agreement with HistoCyte Laboratories Ltd, Tyne, U.K., to be the exclusive multinational distributor of the company’s portfolio of cell line reference products for immunohistochemistry and in situ hybridization....

OPK Up 36% In 5 Days, SLDB Sparkles, CERS Abuzz, ARWR Expects Data In Nov.

OPKO Health Inc. (OPK) has reported better-than-expected financial results for the first quarter ended March 31, 2018.

PierianDx Announces TriCore Reference Laboratories as the Newest Customer to its Partner Sharing Network

PierianDx, the leading clinical genomics technology company that enables precision medicine, announced today that TriCore Reference Laboratories will utilize the company’s Clinical Genomics WorkSpace™ (CGW) platform, the industry’s leading integrated workspace for genomic analytics, classification, interpretation and reporting. TriCore will join mor...

Critical Survey: Cardinal Health

Cardinal Health and Bio-Rad Laboratories are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership. Cardinal Health has higher revenue and earnings than Bio-Rad Laboratories.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks